title: The use of oxybutynin for treating facial hyperhidrosis.
abstract: BACKGROUND
  Facial hyperhidrosis is a disease that may lead patients to serious emotional disturbances. Video-assisted thoracic sympathectomy provides excellent resolution of facial hyperhidrosis, but is associated with certain complications. The most frequent and important complication is compensatory hyperhidrosis. Especially in patients who have undergone resection of the second thoracic ganglion, the risk of severe compensatory hyperhidrosis is higher, which may cause dissatisfaction with the procedure.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the efficacy of the use of low doses of oxybutynin in treating facial hyperhidrosis as well as the level of patient satisfaction with its use.
  
  
  METHODS
  25 patients with facial hyperhidrosis were treated with oxybutynin. The patients underwent 2 evaluations: before and after treatment. These evaluations were used to assess the patients' clinical improvement and quality of life.
  
  
  RESULTS
  We observed that more than 75% of the patients evolved with an improvement in facial hyperhidrosis, and 52% of them presented a great improvement.
  
  
  CONCLUSIONS
  Treatment of facial hyperhidrosis with oxybutynin is a good alternative to sympathectomy, since it presents good results and improves quality of life, in addition to not exposing patients to the risk of experiencing the side effects of sympathectomy.
authors: Clinics Hospital, College of Medicine of the University of Sao Paulo, Sao Paulo, SP, Brazil. nwolosker@yahoo.com.br
authors: Nelson
authors: N
authors: Wolosker
authors: José Ribas Milanez de
authors: JR
authors: Campos
authors: Paulo
authors: P
authors: Kauffman
authors: Marco Antonio
authors: MA
authors: Munia
authors: Samantha
authors: S
authors: Neves
authors: Fábio Biscegli
authors: FB
authors: Jatene
authors: Pedro
authors: P
authors: Puech-Leão
mesh_terms: D000328:Adult; D005145:Face; D005260:Female; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy*; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin